Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?

Ann Oncol. 2022 Oct;33(10):989-991. doi: 10.1016/j.annonc.2022.08.003. Epub 2022 Aug 12.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • BRCA1 Protein / genetics
  • Carcinoma, Ovarian Epithelial
  • Female
  • Humans
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Phthalazines / pharmacology
  • Phthalazines / therapeutic use
  • Piperazines
  • Platinum / therapeutic use
  • Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use

Substances

  • BRCA1 Protein
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Platinum
  • olaparib